Published in J Gen Virol on December 01, 1996
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol (1998) 2.49
Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol (1997) 2.27
Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med (2000) 2.10
Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J Virol (2001) 1.89
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol (1997) 1.71
Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J Virol (1999) 1.37
Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci U S A (2004) 1.30
Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus. J Virol (1999) 1.14
CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J Virol (2005) 1.05
Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J Virol (1998) 0.99
Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef. J Virol (2001) 0.93
Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLoS One (2011) 0.92
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses (2010) 0.86
Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther (2010) 0.85
Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors. Retrovirology (2009) 0.84
Effect of the attenuating deletion and of sequence alterations evolving in vivo on simian immunodeficiency virus C8-Nef function. J Virol (1999) 0.82
Immunization with a live, attenuated simian immunodeficiency virus vaccine leads to restriction of viral diversity in Rhesus macaques not protected from pathogenic challenge. J Virol (1999) 0.78
Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries. Clin Diagn Lab Immunol (2002) 0.78
Host factors determine differential disease progression after infection with nef-deleted simian immunodeficiency virus. J Gen Virol (2014) 0.77
HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen. Hum Vaccin (2009) 0.76
Identification of molecular sub-networks associated with cell survival in a chronically SIVmac-infected human CD4+ T cell line. Virol J (2014) 0.75
AIDS vaccine development: let a thousand flowers bloom. J Clin Pathol (1998) 0.75
Hospitalization costs associated with homelessness in New York City. N Engl J Med (1998) 5.90
Improvement of PCR amplified DNA sequencing with the aid of detergents. Nucleic Acids Res (1990) 5.13
Hospital characteristics and mortality rates. N Engl J Med (1989) 4.97
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill (2012) 4.95
Nucleotide sequence of the envelope gene of Friend murine leukemia virus. J Virol (1983) 3.41
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol (1987) 3.18
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today (1988) 3.13
Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol (1986) 2.65
Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem (1988) 2.48
Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem (1997) 2.39
Neopterin as a marker for immune system activation. Curr Drug Metab (2002) 2.25
Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science (1999) 2.21
Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. Gastroenterology (1999) 2.20
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol (2000) 2.11
Properties of mouse leukemia viruses. VII. The major viral glycoprotein of friend leukemia virus. Isolation and physicochemical properties. Virology (1974) 2.09
Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology (1997) 2.03
Subregions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals. EMBO J (1986) 2.01
Evaluation of the HCFA model for the analysis of mortality following hospitalization. Health Serv Res (1992) 1.99
Properties of mouse leukemia viruses. VIII. The major viral glycoprotein of Friend leukemia virus. Seroimmunological, interfering and hemagglutinating capacities. Virology (1974) 1.98
Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido-reductase. FEBS Lett (1991) 1.96
Immune activation and psoriasis. Lancet (1991) 1.93
Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes. Mol Cell Biol (1996) 1.86
Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol (1998) 1.83
Association between fulminant hepatic failure and a strain of GBV virus C. Lancet (1996) 1.82
Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med (1990) 1.81
Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis (1997) 1.79
Ioxaglate-induced light and electron microscopic alterations in the renal proximal tubular epithelium of rats. Invest Radiol (1991) 1.75
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol (1995) 1.74
[Production of substantial amounts of Friend leukemia virus by a suspension tissue culture line (Eveline suspension cells) (author's transl)]. Z Naturforsch C (1976) 1.69
Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A (1995) 1.69
Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Mol Med (1996) 1.68
Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem (1989) 1.66
Characteristics of fatal ambulance crashes in the United States: an 11-year retrospective analysis. Prehosp Emerg Care (2001) 1.64
Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity. Virology (1975) 1.63
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS (2001) 1.63
Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J (1993) 1.61
Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol (1998) 1.61
Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem (1989) 1.59
Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses. Virology (1973) 1.59
Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol (1995) 1.56
Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med (1994) 1.55
Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology (1995) 1.55
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
Distribution of human endogenous retrovirus HERV-K genomes in humans and different primates. Hum Genet (1995) 1.52
vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol (1995) 1.51
An evaluation of low-cost progression markers in HIV-1 seropositive Zambians. HIV Med (2000) 1.51
Metabolic disorder as early consequence of simian immunodeficiency virus infection in rhesus macaques. Lancet (1991) 1.48
Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. Virology (1975) 1.48
Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques. Nat Med (1997) 1.48
Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation (1983) 1.47
Properties of mouse leukemia viruses. X. Occurrence of viral structural antigens on the cell surface as revealed by a cytotoxicity test. Virology (1976) 1.47
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer (2002) 1.44
Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes. Virology (1981) 1.43
The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci (1992) 1.42
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene (2006) 1.42
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother (2001) 1.42
Prestige of training programs and experience of bypass surgeons as factors in adjusted patient mortality rates. Med Care (1999) 1.41
[Increased urinary excretion of neopterin in patients with malignant tumors and with virus diseases (author's transl)]. Hoppe Seylers Z Physiol Chem (1979) 1.41
Reducing HIV transmission by seronegative blood. Lancet (1992) 1.41
The relationship between adjusted hospital mortality and the results of peer review. Health Serv Res (1993) 1.40
Evaluation of the adaptive learning environments model. Except Child (1988) 1.40
Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr (1990) 1.39
Altered iron metabolism and the anemia of chronic disease: a role of immune activation. Blood (1992) 1.39
C-type particles produced by a permanent cell line from a leukemic pig. I. Origin and properties of the host cells and some evidence for the occurrence of C-type-like particles. Virology (1974) 1.38
Properties of mouse leukemia viruses. IX. Active and passive immunization of mice against Friend leukemia with isolated viral GP71 glycoprotein and its corresponding antiserum. Virology (1975) 1.37
Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol (1993) 1.36
Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol (2001) 1.35
Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem (1993) 1.35
Identification of a superoxide-generating NADPH oxidase system in human fibroblasts. Biochem J (1991) 1.34
Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol (1983) 1.34